Cue Biopharma, Inc. (CUE) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2024-12-31..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2024-12-31..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2024-12-31..
Borrowing debt
Overview →Financial period ending 2024-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2024-12-31. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2024-12-31. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2024-12-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 0.00 USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 32.19M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | (m) | (m) | (m) | $0.00 | (m) | (m) | $32.19M | (m) |
| 2024-09-30 | (m) | (m) | $4.00M | $1.33M | (m) | (m) | $44.81M | (m) |
| 2024-06-30 | (m) | (m) | $4.00M | $2.29M | (m) | (m) | $42.33M | (m) |
| 2024-03-31 | (m) | (m) | $4.00M | $3.24M | (m) | (m) | $53.95M | (m) |
| 2023-12-31 | (m) | (m) | $4.00M | $4.20M | (m) | $48.51M | $61.53M | (m) |
| 2023-09-30 | (m) | (m) | $4.00M | $5.16M | (m) | $54.69M | $68.89M | (m) |
| 2023-06-30 | (m) | (m) | $4.00M | $6.12M | (m) | $57.89M | $73.16M | (m) |
| 2023-03-31 | (m) | (m) | $3.00M | $7.08M | (m) | $66.20M | $81.68M | (m) |
| 2022-12-31 | (m) | (m) | $2.00M | $8.03M | (m) | $76.29M | $91.28M | (m) |
| 2022-09-30 | (m) | (m) | $1.00M | $8.99M | (m) | $59.18M | $76.30M | (m) |
| 2022-06-30 | (m) | (m) | (m) | $9.91M | (m) | $66.13M | $84.75M | (m) |
| 2022-03-31 | (m) | (m) | (m) | $9.86M | (m) | $67.93M | $90.70M | (m) |
| 2021-12-31 | (m) | (m) | (m) | $0.00 | (m) | $64.37M | $83.40M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |